Clinical trial
Cardiac Resynchronization Therapy in Previously Untreatable and High Risk…
NCT02922036 · EBR Systems, Inc., Industry · Active, not recruiting
Key facts
| NCT number | NCT02922036 |
|---|---|
| Title | Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients |
| Official title | Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non-Responders, Previously Untreatable and High Risk Upgrade Patients (SOLVE CRT) |
| Acronym | SOLVE-CRT |
| Lead sponsor | EBR Systems, Inc., Industry |
| Status | Active, not recruiting |
| Study type | Interventional |
| Conditions | Heart Failure |
| Intervention type | Device |
| Interventions | WiSE System |
| Enrollment | 300 |
| Start date | Jan 17, 2018 |
| Primary completion | Jun 1, 2026 |
| Completion | Jun 1, 2026 |
| First posted | Oct 3, 2016 |
| Last update posted | Jul 9, 2025 |
| Countries | Australia, France, Germany, Italy, Netherlands, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: